Deltex Medical Group awarded Innovative Technology contract
Anita Riotta
Company News- 2 min read
09:38, 2nd July 2019

Deltex Medical Group (DEMG) FOLLOW has received an Innovative Technology contract from Vizient Inc. the largest member-driven health care performance improvement company in the United States. 

Vizient awards such contracts to technologies that “identify breakthrough solutions that can improve patient care or reduce the risk of harm to patients or providers, while simultaneously raising the standard of patient care and safety.”

Based on the recommendation of hospital experts in haemodynamics, Deltex’s focus, Vizient has ordered the CardioQ-EDM+, a device that measures blood flow velocity in the central circulation in real time. 

The validation of receiving this contract builds on Deltex’s reputation as “the only company in the enhanced haemodynamic space to have built a robust evidence base demonstrating both the clinical and economic benefits of its core technology.”

CEO of Deltex Medical, Andy Mears commented, “The Board is appreciative of the award of this prestigious Vizient Innovative Technology contract, which recognises the important role the CardioQ-EDM+ plays in improving patient safety during and after surgery.”

For more news and updates from Deltex Medical Group: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist